Niox Flex a Nitric Oxide Monitoring System

NIOX Flex is the successor of NIOX, the first tailor-made Nitric Oxide Monitoring System. NIOX Flex measures NO in exhaled air according to ATS/ERS equipment recommendations and is cleared by FDA, for routine clinical use in asthma patients (1), (2), (3).

NIOX Flex measures exhaled nitric oxide to evaluate responsiveness of anti-inflammatory therapy in asthma patients. Put simply, NIOX Flex lets you see more than your asthma patients can tell you.

NIOX Flex uses the high sensitivity and specificity of a chemiluminescence gas analyzer, together with integrated software, to accurately measure NO molecules at very low concentrations.

Despite the advanced technology employed, the device is very easy to use and is suitable not only for adults, but also for children age 4 and up.

Intended Use

NIOX Flex measures Nitric Oxide (NO) in human breath. Nitric Oxide is frequently increased in some inflammatory processes such as asthma. The fractional NO concentration in expired breath (FE_NO) can be measured by NIOX Flex with assurance that such measurements are repeatable and according to guidelines for NO measurement established by the American Thoracic Society.

Measurement of FE_NO by NIOX Flex is a quantitative, non-invasive, simple and safe method to measure the decrease in FE_NO concentration in asthma patients that often occurs after treatment with anti-inflammatory pharmacological therapy, as an indication of the therapeutic effect in patients with elevated FE_NO levels. NIOX Flex is suitable for children, approximately 4–17 years, and adults 18 years and older.

FE_NO measurements provide the physician with means of evaluating an asthma patient’s response to anti-inflammatory therapy, as an adjunct to established clinical and laboratory assessments in asthma. NIOX Flex should only be used by trained physicians, nurses, respiratory therapists and laboratory technicians. NIOX Flex cannot be used with infants or by children approximately under the age of 4, as measurement requires patient cooperation. NIOX Flex should not be used in critical care, emergency care or in anesthesiology.

Do you already have a NIOX system? Rebuild your NIOX to a NIOX Flex!

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine, markets NIOX^® Flex and NIOX MINO^®. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

More information about Aerocrine and nitric oxide as an inflammatory marker.